BIOTRONIK- Safety and Performance Registry for an All Comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice III- ELADIS
Phase of Trial: Phase IV
Latest Information Update: 03 Oct 2017
Price : $35 *
At a glance
- Drugs Sirolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms BIOFLOW-III
- Sponsors BIOTRONIK
- 26 Sep 2017 Status changed from active, no longer recruiting to completed.
- 08 Sep 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrial.gov.
- 14 Apr 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrial.gov record.